A Study of MGC028 in Participants With Advanced Solid Tumors
← catalyst calendarNCT06723236 · readout ≤ 103 d
Sponsored by MacroGenics (industry) · MGNX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
124estimated
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-13 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumors
- NSCLC Adenocarcinoma
- Cholangiocarcinoma
- Pancreatic Carcinoma
- Colorectal Carcinoma
Intervention
- Biological: MGC028
Primary outcome
what the primary-completion date above is the date OFNumber and Types of Adverse Events (AEs) in Participants Receiving MGC028
measured Throughout the study treatment and safety follow up period, up to 25 months
Publications
- PMID 41166694 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · MGNX's whole pipeline · Catalyst calendar · Every registered study · What changed